Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Plaque in the arteries can sometimes be partially reduced or stabilized, but it is rarely eliminated completely; the realistic goal for most people is shrinking the soft, lipid-rich portion of plaque and hardening its outer cap so it is less likely to rupture and cause a heart attack or stroke. Aggressive LDL cholesterol lowering with statins, ezetimibe, or PCSK9 inhibitors has been shown in imaging studies to regress plaque volume, and these effects are strengthened by blood pressure control, quitting smoking, weight and blood sugar management, a fiber-rich low saturated fat diet, and regular aerobic activity. How much reversal is possible depends on factors such as your age, how calcified the plaque already is, your LDL and Lp(a) levels, diabetes status, and how early treatment begins, so outcomes vary widely from person to person. There are several important details and warning signs to consider, including symptoms like chest pressure, breathlessness, or leg pain with walking that may signal advanced disease, so see below to understand more.
If you are wondering whether your symptoms point to narrowed arteries or something else entirely, guessing is the riskiest option, and a few minutes of structured questions can help you frame the right conversation with a clinician, so take a free, instant, online symptom check to better understand what may be going on and what steps to take next.
Last reviewed for medical accuracy: 09/24/2026
Plaque buildup—also known as atherosclerosis—occurs when fats, cholesterol, and other substances accumulate on artery walls. Over time, this narrows vessels, reducing blood flow and raising the risk of heart attack or stroke. While you can’t “erase” old plaques overnight, a combination of lifestyle changes, medications, and medical monitoring can slow progression—and in some cases, even shrink plaque deposits. Here’s how to reduce plaque in arteries, based on credible guidelines and studies.
Research shows you can:
According to the American Heart Association and major clinical trials, combining multiple approaches offers the best chance of plaque regression.
Adopting heart-healthy habits is the foundation for how to reduce plaque in arteries.
Lifestyle changes are essential, but many people need medications to reverse or halt plaque progression.
Work with your doctor to find the right combination, monitor side effects, and adjust doses.
Some supplements show promise but should never replace prescribed treatments:
Always discuss with your healthcare provider before starting any supplement.
Regular check-ups help track progress and catch problems early:
Adjust your plan based on results—if LDL remains high, intensify diet, exercise, or medications.
Severe blockages sometimes require intervention:
These procedures relieve symptoms and improve blood flow but don’t cure the underlying disease—you still need ongoing risk-factor management.
If you ever experience chest pain, shortness of breath, dizziness, or unexplained fatigue, don’t wait. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you need urgent care or should see your doctor.
Always speak to a doctor about any life-threatening or serious concerns. Early detection and treatment save lives.
Reversing or reducing plaque in arteries is challenging but achievable with a comprehensive approach:
By combining these strategies, you can stabilize existing plaques, shrink fatty deposits, and significantly lower your risk of heart attack or stroke. Stay proactive, stay informed, and stay connected with your healthcare team.
(References)
* Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013 Oct;13(10):709-21. doi: 10.1038/nri3520. Epub 2013 Sep 2. PMID: 23995626; PMCID: PMC4357520.
* Tabas I, Bornfeldt KE. Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res. 2016 Feb 19;118(4):653-67. doi: 10.1161/CIRCRESAHA.115.306256. PMID: 26892964; PMCID: PMC4762068.
* Ouimet M, Barrett TJ, Fisher EA. HDL and Reverse Cholesterol Transport. Circ Res. 2019 May 10;124(10):1505-1518. doi: 10.1161/CIRCRESAHA.119.312617. PMID: 31071007; PMCID: PMC6813799.
* Linton MF, Yancey PG, Tao H, Davies SS. HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy. Circ Res. 2023 May 26;132(11):1521-1545. doi: 10.1161/CIRCRESAHA.123.321563. Epub 2023 May 25. PMID: 37228232; PMCID: PMC10213997.
* Zhao Y, Shao C, Zhou H, Yu L, Bao Y, Mao Q, Yang J, Wan H. Salvianolic acid B inhibits atherosclerosis and TNF-α-induced inflammation by regulating NF-κB/NLRP3 signaling pathway. Phytomedicine. 2023 Oct;119:155002. doi: 10.1016/j.phymed.2023.155002. Epub 2023 Aug 1. PMID: 37572566.
* Hou P, Fang J, Liu Z, Shi Y, Agostini M, Bernassola F, Bove P, Candi E, Rovella V, Sica G, Sun Q, Wang Y, Scimeca M, Federici M, Mauriello A, Melino G. Macrophage polarization and metabolism in atherosclerosis. Cell Death Dis. 2023 Oct 20;14(10):691. doi: 10.1038/s41419-023-06206-z. Epub 2023 Oct 20. PMID: 37863894; PMCID: PMC10589261.
* Cyr Y, Bozal FK, Barcia Durán JG, Newman AAC, Amadori L, Smyrnis P, Gourvest M, Das D, Gildea M, Kaur R, Zhang T, Wang KM, Von Itter R, Schlegel PM, Dupuis SD, Sanchez BF, Schmidt AM, Fisher EA, van Solingen C, Giannarelli C, Moore KJ. The IRG1-itaconate axis protects from cholesterol-induced inflammation and atherosclerosis. Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2400675121. doi: 10.1073/pnas.2400675121. Epub 2024 Apr 2. PMID: 38564634; PMCID: PMC11009655.
* Mocci G, Sukhavasi K, Örd T, Bankier S, Singha P, Arasu UT, Agbabiaje OO, Mäkinen P, Ma L, Hodonsky CJ, Aherrahrou R, Muhl L, Liu J, Gustafsson S, Byandelger B, Wang Y, Koplev S, Lendahl U, Owens GK, Leeper NJ, Pasterkamp G, Vanlandewijck M, Michoel T, Ruusalepp A, Hao K, Ylä-Herttuala S, Väli M, Järve H, Mokry M, Civelek M, Miller CJ, Kovacic JC, Kaikkonen MU, Betsholtz C, Björkegren JLM. Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis. Circ Res. 2024 May 24;134(11):1405-1423. doi: 10.1161/CIRCRESAHA.123.323184. Epub 2024 Apr 19. PMID: 38639096; PMCID: PMC11122742.
* Adkar SS, Leeper NJ. Efferocytosis in atherosclerosis. Nat Rev Cardiol. 2024 Nov;21(11):762-779. doi: 10.1038/s41569-024-01037-7. Epub 2024 May 15. PMID: 38750215.
* Schlegel M, Cyr Y, Newman AAC, Schreyer K, Barcia Durán JG, Sharma M, Bozal FK, Gourvest M, La Forest M, Afonso MS, van Solingen C, Fisher EA, Moore KJ. Targeting Unc5b in macrophages drives atherosclerosis regression and pro-resolving immune cell function. Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2412690121. doi: 10.1073/pnas.2412690121. Epub 2024 Oct 22. PMID: 39436659; PMCID: PMC11536151.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.